Aromatase Expression in Women’s Cancers

  • Serdar E. Bulun
  • Evan R. Simpson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 630)


Estrogen has been positively linked to the pathogenesis and growth of three common women’s cancers (breast, endometrium and ovary). A single gene encodes the key enzyme for estrogen biosynthesis named aromatase, inhibition of which effectively eliminates estrogen production in the entire body. Aromatase inhibitors successfully treat breast cancer, whereas their roles in endometrial and ovarian cancers are less clear. Ovary, testis, adipose tissue, skin, hypothalamus and placenta express aromatase normally, whereas breast, endometrial and ovarian cancers overexpress aromatase and produce local estrogen exerting paracrine and intracrine effects. Tissue specific promoters distributed over a 93 kilobase regulatory region upstream of a common coding region alternatively control aromatase expression. A distinct set of transcription factors regulates each promoter in a signaling pathway-and tissue-specific manner. In cancers of breast, endometrium and ovary, aromatase expression is primarly regulated by increased activity of the proximally located promoter I.3/II region. Promoters I.3 and II lie 215 bp from each other and are coordinately stimulated by PGE2 via a cAMP-PKA-dependent pathway. In breast adipose fibroblasts exposed to PGE2 secreted by malignant epithelial cells, activation of PKC potentiates cAMP-PKA-dependent induction of aromatase. Thus, inflammatory substances such as PGE2 may play important roles in inducing local production of estrogen that promotes tumor growth.


Breast Cancer Ovarian Cancer Endometrial Cancer Aromatase Inhibitor Ovarian Surface Epithelium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Simpson ER, Clyne C, Rubin G et al. Aromatase—a brief overview. Annu Rev Physiol 2002; 64:93–127.PubMedGoogle Scholar
  2. 2.
    Sebastian S, Bulun SE. A highly complex organization of the regulatry region of the human CYP19 (aromatase) gene revealed by the human genome project. J Clin Endocrinol Metab 2001; 86:4600–4602.PubMedGoogle Scholar
  3. 3.
    Simpson ER, Mahendroo MS, Means GD et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev// 1994; 15:342–355.Google Scholar
  4. 4.
    Bulun SE, Simpson ER. Competitive RT-PCR analysis indicates levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs and abdomen of women increase with advancing age. J Clin Endocrinol Metab 1994; 78:428–432.PubMedGoogle Scholar
  5. 5.
    Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973; 36:207–214.PubMedGoogle Scholar
  6. 6.
    MacDonald PC, Madden JD, Brenner PF et al. Origin of estrogen in normal men and in women with testicular fem inization. J. Clin Endocrinol Metab 1979; 49:905–916.PubMedGoogle Scholar
  7. 7.
    Shozu M, Sebastian S, Takayama K et al. Estrogen excess associated with novel gainoffunction mutations affecting the aromatase gene. N Engl J Med 2003; 348(19):1855–1865.PubMedGoogle Scholar
  8. 8.
    Mahendroo MS, Mendelson CR, Simpson ER. Tissuespecific and hormonallycontrolled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J Biol Chem 1993; 268:19463–19470.PubMedGoogle Scholar
  9. 9.
    Bulun S. Aromatase deficiency and estrogen resistance: from molecular genetics to clinic. Semin Reprod Med 2000; 2000:31–39.Google Scholar
  10. 10.
    Zhao Y NJ, Bulun SE, Mendelson CR et al. Aromatase P450 gene expression in human adipose tissue: Role of a Jak/STAT pathway in regulation of the adiposespecific promoter. J Biol Chem 1995; 270:16449–16457.PubMedGoogle Scholar
  11. 11.
    Kamat A, Alcorn J, Kunczt C et al. Characterization of the regulatory regions of the human aromatase (P450arom) gene involved in placentaspecific expression. Mol Endocrinol 1998; 12:1764–1777.PubMedGoogle Scholar
  12. 12.
    Jiang B, Kamat A, Mendelson C. Hypoxia prevents induction of aromatase expression in human trophoblast cells in culture: potential inhibitory role of the hypoxia-inducible transcription factor Mash-2 (mammalian achaetescute homologous protein-2). Mol Endocrinol 2000; 14:1661–1673.PubMedGoogle Scholar
  13. 13.
    Zhao Y, Agarwal VR, Mendelson CR et al. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996; 137(12):5739–5742.PubMedGoogle Scholar
  14. 14.
    Bulun SE, Noble LS, Takayama K et al. Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol 1997; 61:133–139.PubMedGoogle Scholar
  15. 15.
    Bulun SE, Lin Z, Imir G et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005; 57(3):359–383.PubMedGoogle Scholar
  16. 16.
    Bulun SE, Economos K, Miller D et al. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. J Clin Endocrinol Metab 1994; 79:1831–1834.PubMedGoogle Scholar
  17. 17.
    Burnett AF BA, Amezcua C. Anastrozole, an aromatase inhibitor and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy. Gynecol Oncol 2004; 94:832–834.PubMedGoogle Scholar
  18. 18.
    Rose PG BV, VanLe L, Bell J et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2000; 78(2):212–216.PubMedGoogle Scholar
  19. 19.
    Somigliana E, Vigano P, Parazzini F et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006; 101(2):331–341.PubMedGoogle Scholar
  20. 20.
    Vercellini P, Scarfone G, Bolis G et al. Site of origin of epithelial ovarian cancer: the endometriosis connection. Br J Obst Gynec 2000; 107(9):1155–1157.Google Scholar
  21. 21.
    Schildkraut JM, Calingaert B, Marchbanks PA et al. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002; 94(1):32–38.PubMedGoogle Scholar
  22. 22.
    Rodriguez GC, Nagarsheth NP, Lee KL et al. Progestininduced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factorbeta. J Natl Cancer Inst 2002; 94(1):50–60.PubMedGoogle Scholar
  23. 23.
    Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003; 1:73.PubMedGoogle Scholar
  24. 24.
    Papadimitriou CA, Markaki S, Siapkaras J et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Longterm results of a phase II study. Oncology 2004; 66(2):112–117.PubMedGoogle Scholar
  25. 25.
    Bowman A, Gabra H, Langdon SP et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002; 8(7):2233–2239.PubMedGoogle Scholar
  26. 26.
    del Carmen MG, Fuller AF, Matulonis U et al. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol 2003; 91(3):596–602.PubMedGoogle Scholar
  27. 27.
    Lee EJ DM, Hughes JL, Lee JH et al. Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapy. Int J Gynecol Cancer 2006; 16(Suppl 1):295–299.PubMedGoogle Scholar
  28. 28.
    Meng L, Zhou J, Hironobu S et al. TNFalpha and IL-11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively downregulating C/EBPalpha and PPAR gamma: mechanism of desmoplastic reaction. Cancer Res 2001; 61:2250–2255.PubMedGoogle Scholar
  29. 29.
    Zhou J, Gurates B, Yang S et al. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by C/EBP beta. Cancer Res 2001; 61:2328–2334.PubMedGoogle Scholar
  30. 30.
    Haagensen CD. Diseases of the breast. Vol. 3rd. Philadelphia: W.B. Saunders Company; 1986.Google Scholar
  31. 31.
    Agarwal VR, Bulun SE, Leitch M et al. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 1996; 81:3843–3849.PubMedGoogle Scholar
  32. 32.
    Harada N, Utsumi T, Takagi Y. Tissuespecific expression of the human aromatase cytochrome P450 gene by alternative use of multiple exons I and promoters and switching of tissue-specific exons I in carcinogenesis. Proc Natl Acad Sci U S A (USA) 1993; 90:11312–11316.Google Scholar
  33. 33.
    Utsumi T, Harada N, Maruta M et al. Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. J Clin Endocrinol Metab 1996; 81:2344–2349.PubMedGoogle Scholar
  34. 34.
    Zhou C, Zhou D, Esteban J et al. Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 1996; 59:163–171.PubMedGoogle Scholar
  35. 35.
    Sebastian S, Takayama K, Shozu M et al. Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is upregulated in breast cancer tissue. Mol Endocrinol 2002; 16:2243–2254.PubMedGoogle Scholar
  36. 36.
    MacDonald PC, Grodin JM, Siiteri PK. The utilization of plasma androstenedione for estrone production in women. In: Ebling CGc-eFJG, ed. Excerpta Medica Int. Congr Series No. 184, Progress in Endocrinology, Proceedings of the Third International Congress of Endocrinology 1968 (Mexico). Amsterdam: Excerpta Medica Foundation; 1968:770–776.Google Scholar
  37. 37.
    Hemsell DL GJ, Brenner PF, Siiteri PK et al. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrin Metab 1974; 38:476–479.Google Scholar
  38. 38.
    MacDonald PC, Edman CD, Hemsell DL et al. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978; 130:448–455.PubMedGoogle Scholar
  39. 39.
    Hankinson S, Willett W, Manson J et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;90:1292–1299.Google Scholar
  40. 40.
    Huang Z, Hankinson SE, Colditz GA et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997; 278:1407–1411.PubMedGoogle Scholar
  41. 41.
    Brodie A, Lu Q, Liu Y et al. Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 1999; 6:205–210.PubMedGoogle Scholar
  42. 42.
    Brodie A, Lu Q, Long B. Aromatase and its inhibitors. J Steroid Biochem and Mol Biol 1999; 69:205–210.Google Scholar
  43. 43.
    Chetrite G, Cortes-Prieto J, Philippe J et al. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal and in cancerous, human breast tissues. J Steroid Biochemistry and Molecular Biology 2000; 72:23–27.Google Scholar
  44. 44.
    Geisler J, Berntsen H, Lonning P. A novel HPLCRIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancear tissue. J Steroid Biochemistry_& Molecular Biology 2000; 72:259–264.Google Scholar
  45. 45.
    Van Landeghem AAJ, Poortman J, Nabuurs M et al. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985; 45:2907–2912.PubMedGoogle Scholar
  46. 46.
    O’Neill JS, Elton RA, Miller WR. Aromatase activity in adipose tissue from breast quadrants: a link with tumor site. British Medical Journal 1988; 296:741–743.PubMedGoogle Scholar
  47. 47.
    Bulun SE, Price TM, Mahendroo MS et al. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993; 77:1622–1628.PubMedGoogle Scholar
  48. 48.
    Sasano H, Nagura H, Harada N et al. Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum Pathol 1994; 25:530–535.PubMedGoogle Scholar
  49. 49.
    Reed MJ, Topping L, Coldham NG et al. Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors. J Steroid Biochem Mol Biol 1993;44:589–596.PubMedGoogle Scholar
  50. 50.
    Agarwal VR, Ashanullah CI, Simpson ER et al. Alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women. J Clin Endocrinol Metab 1997; 82:70–74.PubMedGoogle Scholar
  51. 51.
    Agarwal VR, Bulun SE, Simpson ER. Quantitative detection of alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in aromataseexpressing human cells by competitive RT-PCR. Mol Cellular Probes 1995; 9:453–464.Google Scholar
  52. 52.
    Yue W, Zhou D, Chen S et al. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 1994; 54:5092–5095.PubMedGoogle Scholar
  53. 53.
    Tekmal R, N K, Gill K et al. Aromatase overexpression and breast hyperplasia, an in vivo model — continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens and aromatase inhibitors abrogate these preneoplasatic changes in mammary glands. Endocr Relat Cancer 1999; 6:307–314.PubMedGoogle Scholar
  54. 54.
    Kovacic A. SC, Simpson ER, Clyne CD. Inhibition of aromatase transcription via promoter II by short heterodimer partner in human preadipocytes. Mol Endocrinol 2004; 18:252–259.PubMedGoogle Scholar
  55. 55.
    Price T, Aitken J, Head J et al. Determination of aromatase cytochrome P450 messenger RNA in human breast tissues by competitive polymerase chain reaction (PCR) amplification. J Clin Endocrinol Metab 1992; 74:1247–1252.PubMedGoogle Scholar
  56. 56.
    Ackerman GE, Smith ME, Mendelson CR et al. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 1981; 53:412–417.PubMedGoogle Scholar
  57. 57.
    Santen RJ, Martel J, Hoagland M et al. Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 1994; 79:627–632.PubMedGoogle Scholar
  58. 58.
    Sasano H, Frost A, Saitoh R et al. Aromatase and 17beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 1996; 81:4042–4046.PubMedGoogle Scholar
  59. 59.
    Brodie A, Long B, Lu Q. Aromatase expression in the human breast. Breast Cancer Res Treat 1998; 49:S85–91.PubMedGoogle Scholar
  60. 60.
    Sasano H, Edwards DP, Anderson TJ et al. Validation of new aromatase monoclonal antibodies for immunohisto chemistry: progress report. J Steroid Biochem Mol Biol 2003; 86:239–244.PubMedGoogle Scholar
  61. 61.
    Pauley R, Santner S, Tait L et al. Regulation of CYP19 aromatase transcription in breast stromal fibroblasts. J Clin Endocrin and Metabo 2000; 85:837–846.Google Scholar
  62. 62.
    Crichton MB, Nichols JE, Zhao Y et al. Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells and adipose stromal cells. Mol Cell Endocrinol 1996; 118:215–220.PubMedGoogle Scholar
  63. 63.
    Hube F, Hauner H. The two tumor necrosis factor receptors mediate opposite effects on differentiation and glucose metabolism in human adipocytes in primary culture. Endocrinology 2000; 141:2582–2588.PubMedGoogle Scholar
  64. 64.
    Deb S AS, Imir AG, Yilmaz MB et al. Estrogen regulates expression of tumor necrosis factor receptors in breast adipose fibroblasts. J Clin Endocrinol Metab 2004; 89:4018–4024.PubMedGoogle Scholar
  65. 65.
    Clyne CD, Speed CJ, Zhou J et al. Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J Biol Chem 2002; 277:20591–20597.PubMedGoogle Scholar
  66. 66.
    Karuppu D, Kalus A, Simpson Er et al. Aromatase and prostaglandin inter-relationships in breast adipose tissue: significance for breast cancer development. Breast Cancer Res Treat 2002; 76:103–109.PubMedGoogle Scholar
  67. 67.
    Brueggemeir RW, Quinn AL, Parrett ML et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999 (140):27–35.Google Scholar
  68. 68.
    Richards JA, Petrel TA, Brueggemeier RW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem 2002; 80:203–212.Google Scholar
  69. 69.
    Deb S, Jianfeng Z, Amin SA et al. A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts. J Biol Chem 2006; 281 (5):2585–2597.PubMedGoogle Scholar
  70. 70.
    Chen S, Itoh T, Wu K et al. Transcriptional regulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol 2002; 83:93–99.PubMedGoogle Scholar
  71. 71.
    Ruohola J, Valve E, Karkkainen M et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999; 149:29–40.PubMedGoogle Scholar
  72. 72.
    Nakamura J, Lu Q, Aberdeen G et al. The effect of estrogen on aromatase and vascular endothelial growth factor messenger ribonucleic acid in the normal nonhuman primate mammary gland. J Clin Endocrinol Metab 1999; 84:1432–1437.PubMedGoogle Scholar
  73. 73.
    Nakamura J, Savinov A, Lu Q et al. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology 1996; 137:5589–5596.PubMedGoogle Scholar
  74. 74.
    Shekhar M, Werdell J, Tait L. Interaction with endothelial cells is a prerequisite for branching ductalalveolar morphogenesis and hyperplasia of preneoplastic human breast epithelial cells: regulation by estrogen. Cancer Res 2000; 60:439–449.PubMedGoogle Scholar
  75. 75.
    Santen R. To block estrogen’s synthesis or action: that is the question. J Clin Endocrinol Metab 2002; 87:3007–3012.PubMedGoogle Scholar
  76. 76.
    Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131–2139.PubMedGoogle Scholar
  77. 77.
    Baum M, Buzdar A, Cuzick et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98(9):1802–1810.PubMedGoogle Scholar
  78. 78.
    Buzdar AU VI, Sainsbury R. The impact of hormone receptor status on the clinical efficacy of the newgeneration aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Breast J 2004; 10:211–217.PubMedGoogle Scholar
  79. 79.
    Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as firstline therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18:3748–3757.PubMedGoogle Scholar
  80. 80.
    Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl Med 2003; 349(19):1793–1802.Google Scholar
  81. 81.
    Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen an first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596–2606.PubMedGoogle Scholar
  82. 82.
    Milla-Santos A, Milla L, Portella J et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Onc 2003; 26:317–322.Google Scholar
  83. 83.
    Paridaens R, Dirix L, Lohrisch C et al. Mature results of a rondomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14:1391–1398.Google Scholar
  84. 84.
    Lu Q, Yue W, Wang J et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 1998; 50:63–71.Google Scholar
  85. 85.
    Dixon J, Renshaw L, Bellamy C et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-cencer study. Clin Cancer Res 2000; 6:2229–2235.PubMedGoogle Scholar
  86. 86.
    Bulun SE, Yang S, Fang Z et al. Role of aromatase in endometrial disease. J Steroid Biochem Mol Biol 2001; 79:19–25.PubMedGoogle Scholar
  87. 87.
    Inoue M, Kyo S, Fujita M et al. Coexpression of the ckit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994; 54(11):3049–3053.PubMedGoogle Scholar
  88. 88.
    Nagasako S, Asanuma N, Nagata Y. [Plasma concentration of estrogens and androgens in postmenopausal women with or without endometrial cancer]. Nippon Sanka Fujinka Gakkai Zasshi 1988; 40(60):707–713.PubMedGoogle Scholar
  89. 89.
    Potischman N, Swanson CA, Siiteri P et al. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 1996; 88(11):756–758.Google Scholar
  90. 90.
    Sherman ME, Sturgeon S, Brinton LA et al. Risk factors and hormone levels in patients with resous and endometrioid uterine carcinomas. Mod Pathol 1997; 10(10):963–968.PubMedGoogle Scholar
  91. 91.
    Vermeulen-Meiners C, Poortman J, Haspels AA et al. The endogenous concentration of estradiol and estrone in pathological human postmenopausal endometrium. J Steroid Biochem 1986; 24(5):1073–1078.PubMedGoogle Scholar
  92. 92.
    Berstein LM, Tchernobrovkina AE, Gamajunova VB et al. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 2003; 129(4):245–249.PubMedGoogle Scholar
  93. 93.
    Yamamoto T, Kitawaki J, Urabe M et al. Estrogen production of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J Steroid Biochem Mol Biol 1993; 44:463–468.PubMedGoogle Scholar
  94. 94.
    Watanabe K, Sasano H, Harada N et al. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization and biochemical studies. American Journal of Pathology 1995; 146:491–500.PubMedGoogle Scholar
  95. 95.
    Berstein L, Maximov S, Gershfeld E et al. Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. Eur J Obstet Gynecol Reprod Biol 2002; 105(2):161–165.PubMedGoogle Scholar
  96. 96.
    Sasano H, Sato S, Ito K et al. Effects of aromatase inhibitors on the pathobiology of the human breast endometrial and ovarian carcinoma. Endocr Relat Cancer 1999; 6(2):197–204.PubMedGoogle Scholar
  97. 97.
    Yamamoto T, Fukuoka M, Fujimoto Y et al. Inhibitory effect of a new androstenedione derivative, 14 alpha-hydroxy-4-androstene-3,6,17-trione (14 alpha-OHAT) on aromatase activity of human uterine tumors. J Steroid Biochem 1990; 36:517–521.PubMedGoogle Scholar
  98. 97.
    Duffy S, Jackson TL, Lansdown M et al. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. Bjog 2003; 110(12):1099–1106.PubMedGoogle Scholar
  99. 98.
    Duffy S, Jackson TL, Landswon M et al. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. Bjog 2003; 110(12):1099–1106.PubMedGoogle Scholar
  100. 99.
    Lacey JV Jr, Mink PJ, LKubin JH et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288(3):334–341.PubMedGoogle Scholar
  101. 100.
    Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291(14):1701–1712.PubMedGoogle Scholar
  102. 101.
    Giudice L, Kao L. Endometriosis. Lancet 2004; 364:1789–1799.PubMedGoogle Scholar
  103. 102.
    Zeitoun K, Takayama K, Michael MD et al. Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of SF-1 and COUP-TF to the same cis-acting element. J Mol Endocrinol 1999; 13:239–253.Google Scholar
  104. 103.
    Yang S, Fang Z, Takashi S et al. Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAT? enhancer binding proteins: decreased C/EBPbeta in endometriosis in associated with overexpression of aromatase. J Clin Endocrinol Metab 2002; 87:2336–2345.PubMedGoogle Scholar
  105. 104.
    Gurates B, Sbastian S, Yang S et al. WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometruiotic stromal cells. J Clin Endocrinol Metab 2002; 87:4369–4377.PubMedGoogle Scholar
  106. 105.
    Fang ZJ, Yang S, Gurates G et al. Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue. J Clin Endocrinol Metab 2002; 87:3460–3466PubMedGoogle Scholar
  107. 106.
    Kitawaki J, Noguchi T, Amatsu T et al. Expression of aromatase cytochrome P450 protein and meassenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod 1997; 57:514–519.PubMedGoogle Scholar
  108. 107.
    Noble LS, Takayama K, Putman JM et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997; 82;600–606.PubMedGoogle Scholar
  109. 108.
    Tsai SJ, Wu MH, Lin CC et al. Regulation of steroidogenic acute regulatory protein expression and progesterone production in endometriotic stromal cells. J Clin ENdocrinol Metab 2001; 86:5765–5773.PubMedGoogle Scholar
  110. 109.
    Sun HS, Hsiao KY, Hsu CC et al. Transactivatio nof steroidogenic acute regulatory protein in human endometriotic stromalcells is mediated by the prostaglandin EP2 receptor. Endocrinology 2003; 144:3934–3942PubMedGoogle Scholar
  111. 110.
    Langdon SP, Hawkes MM, Lawrie SS et al. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer 1990; 62(2):213–216.PubMedGoogle Scholar
  112. 111.
    Langdon Sp, Ritchie A, Young K et al. Contrasting effects of 17 beta-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo. Int J Cancer 1993; 55(3):459–464.PubMedGoogle Scholar
  113. 112.
    Langdon SP, Crew AJ, Ritchie AA et al. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur J Cancer 1994; 30A(5):682–686.PubMedGoogle Scholar
  114. 113.
    Langdon SP, Hirst GL, Miller EP et al. The reguation of growth and protein expression by estrogen in vitro: a study of 8 hhuman ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 1994; 50(3–4):131–135.PubMedGoogle Scholar
  115. 114.
    Langdon SP, Gabra H, Bartlett JM et al. Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. Clin Cancer Res 1998; 4(9):2245–2251.PubMedGoogle Scholar
  116. 115.
    Simpson BJ, Langdon SP, Rabias GJ et al. Estrogen regulation of transforming growth factor-alpha in ovarian cancer. J Steroid Biochem Mol Biol 1998; 64(3–4):137–145.PubMedGoogle Scholar
  117. 116.
    Langdon SP, Rabiasz GJ, Hirst GL et al. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res 1995; 1(12):1603–1609.PubMedGoogle Scholar
  118. 117.
    Hatch KD, Beecham JB, Blessing JA et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of secondline therapy in 105 patients. Cancer 1991; 68(2):269–271.PubMedGoogle Scholar
  119. 118.
    Markman M, Iseminger KA, Hatch KD et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 1996; 62(1):4–6.PubMedGoogle Scholar
  120. 119.
    Ahlgren JD, Ellison NM Gottlieb RJ et al. Hromonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11(10):1957–1968.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2008

Authors and Affiliations

  1. 1.Department of Obstetric and GynecologyNorthwestern UniversityChicagoUSA

Personalised recommendations